Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride
- PMID: 28322485
- DOI: 10.1111/hepr.12894
Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride
Abstract
Aim: Pruritus is one of the complications of chronic liver disease, and it is important to investigate the predictors.
Methods: Six hundred and seventy-three consecutive Japanese patients with chronic liver disease were retrospectively investigated for itch severity. Furthermore, 138 of all 673 patients were introduced to nalfurafine hydrochloride, and the improvement of itch severity was evaluated. The itch severity was self-assessed using the pruritus scores by Kawashima's criteria and visual analog scale.
Results: Two hundred and twenty-nine of the 673 patients (34.0%) were evaluated as 1 point or more of pruritus severity of Kawashima's criteria, and 46 patients (6.8 %) as 3 points or more. Multivariate analysis established that being negative for hepatitis B surface antigen (HBsAg) and presence of hepatocellular carcinoma (HCC) were significant determinants of pruritus (≥1 point of Kawashima's criteria), and being negative for HBsAg and having lower levels of platelet count were significant determinants of severe pruritus (≥3 points). Ninety-three of the 138 patients (67.4%) with nalfurafine hydrochloride indicated improvement of itch, defined as a decrease in VAS of 50 mm or more. There were no significant differences in treatment efficacy of nalfurafine hydrochloride, regardless of the three predictors of pruritus (HBsAg, HCC and platelet count).
Conclusion: The present retrospective study indicated the predictors for pruritus, based on the large number of patients with chronic liver disease. Furthermore, this study demonstrated that nalfurafine hydrochloride may be useful for pruritus, regardless of the predictors.
Keywords: Kawashima's criteria; hepatitis B virus; hepatocellular carcinoma; nalfurafine hydrochloride; platelet count; pruritus; visual analog scale; κ-opioid receptor agonist.
© 2017 The Japan Society of Hepatology.
Similar articles
-
Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.Sci Rep. 2022 May 4;12(1):7311. doi: 10.1038/s41598-022-11431-1. Sci Rep. 2022. PMID: 35508514 Free PMC article.
-
Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride.Sci Rep. 2021 Feb 4;11(1):3015. doi: 10.1038/s41598-021-82566-w. Sci Rep. 2021. PMID: 33542298 Free PMC article.
-
Post-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus.Hepat Med. 2022 May 2;14:37-66. doi: 10.2147/HMER.S352775. eCollection 2022. Hepat Med. 2022. PMID: 35530746 Free PMC article.
-
Nalfurafine hydrochloride to treat pruritus: a review.Clin Cosmet Investig Dermatol. 2015 May 11;8:249-55. doi: 10.2147/CCID.S55942. eCollection 2015. Clin Cosmet Investig Dermatol. 2015. PMID: 26005355 Free PMC article. Review.
-
Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.Drugs Today (Barc). 2009 May;45(5):323-9. doi: 10.1358/dot.2009.45.5.1362067. Drugs Today (Barc). 2009. PMID: 19584962 Review.
Cited by
-
Factors Related to Sleeping Disorder Due to Pruritus in Patients with Chronic Liver Disease.Intern Med. 2021;60(20):3195-3203. doi: 10.2169/internalmedicine.7129-21. Epub 2021 Oct 15. Intern Med. 2021. PMID: 34657905 Free PMC article.
-
Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis.Acta Derm Venereol. 2022 Feb 22;102:adv00653. doi: 10.2340/actadv.v102.310. Acta Derm Venereol. 2022. PMID: 35088869 Free PMC article.
-
Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.BMC Gastroenterol. 2019 Oct 24;19(1):169. doi: 10.1186/s12876-019-1092-z. BMC Gastroenterol. 2019. PMID: 31651244 Free PMC article.
-
Infection phase is a predictor of pruritus in patients with hepatitis B virus infection.Biomed Rep. 2019 Aug;11(2):63-69. doi: 10.3892/br.2019.1224. Epub 2019 Jun 21. Biomed Rep. 2019. PMID: 31338192 Free PMC article.
-
Novel Kappa-Opioid Receptor Agonist for the Treatment of Cholestatic Pruritus: Systematic Review.JMIR Dermatol. 2022 May 2;5(2):e30737. doi: 10.2196/30737. JMIR Dermatol. 2022. PMID: 37632854 Free PMC article. No abstract available.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials